Company / Operating Cash Flow
Tyra Biosciences, Inc. Operating Cash Flow History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$69.8M
FY2024
5-year range
-$69.8M / -$7.8M
FY2020-FY2024
Trend
-39.2%
vs FY2023
Sector context
#104 of 216
Health Care
What the data says
At -$70M, Tyra Biosciences, Inc.'s operating cash flow ranks #104 of 216 in the Health Care sector. Declined from -$50M to -$70M over the past 2 years.
Based on SEC 10-K filings.
-$70M in FY2024.
Declined from -$50M to -$70M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#104 of 216 in Health CareTop 48% of 216This company -$69.8M Sector average $658.7M
▼
-110.6% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow decreased 39.2% year-over-year.
- Ranks #104 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 6.83 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$69.8M | -39.2% |
| FY2023 | -$50.1M | +0.3% |
| FY2022 | -$50.3M | -111.8% |
| FY2021 | -$23.7M | -205.9% |
| FY2020 | -$7.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026